Compare DexCom, Inc. (DXCM) vs Kinross Gold Corporation (KGC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Kinross Gold Corporation — how do they compare? DexCom, Inc. trades at $84.14 (market cap $31.86B), while Kinross Gold Corporation trades at $23.72 (market cap $27.62B). The key difference: DexCom, Inc. is the larger of the two by market cap, and Kinross Gold Corporation pays a 0.69% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Kinross Gold Corporation for 53 Days on average.
| DXCM | KGC | |
|---|---|---|
Market Cap | $31.86B | $27.62B |
Volume | 3,607,070 | 6,347,266 |
Sector | Health | Basic Materials |
52-Week High | $92.34 | $38.06 |
52-Week Low | $54.84 | $22.47 |
Typical Hold Time | 62 Days | 53 Days |
Enterprise Value | $31.32B | $25.70B |
Dividend Yield | — | 0.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.03, down 0.32% on the day, with strong fundamental performance including three consecutive quarterly EPS beats and robust 20.12% net income margin. The stock shows bearish technical signals with price near pivot point support at $84, while analyst consensus remains overwhelmingly positive with 81% buy ratings and $95.07 price target representing 13% upside potential. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
DXCM presents a compelling growth story with expanding profit margins and consistent earnings outperformance, though technical weakness and premium valuation create near-term headwinds. The company's leadership in continuous glucose monitoring and Type 2 diabetes market expansion provide long-term catalysts, while competition and reimbursement risks require monitoring.
Kinross Gold (KGC) trades at $23.82, up 2.76% today, but faces a bearish technical signal despite strong fundamentals. The company reported robust earnings, beating estimates for three consecutive quarters, with 2025 revenue of $7.05 billion and net income of $2.39 billion. However, recent news highlights production guidance cuts and legal investigations, creating mixed sentiment. Valuation ratios appear attractive with a P/E of 8.87 and EV/EBITDA of 4.59, while analyst consensus remains bullish with a $38.80 price target.
The outlook for KGC is cautiously optimistic, driven by strong cash flow and gold price resilience, but near-term risks include operational setbacks and legal overhangs. Investment opportunity lies in its undervaluation and shareholder returns, yet investors must weigh production volatility and cost pressures against fundamental strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Kinross Gold Corporation
Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.
Read more on KGC →
